Taken together, we demonstrated that PCAT6 could modulate CRC chemoresistance to 5‐FU‐based chemotherapy through miR‐204/HMGA2/PI3K; PCAT6 represents a promising target for dealing with CRC chemoresistance. Here, HMGA2 is linked to colorectal carcinoma.